Edesa Biotech Inc. shares fell nearly 13% in Thursday premarket trading after the clinical-stage biopharmaceutical company priced a $25 million public offering, renewing dilution concerns among existing shareholders. The decline followed an 18.27% drop in Wednesday after-hours trading, which left the stock at $4.70, and came four days after the company released fiscal third-quarter earnings. The offering comprises 3.87 million common shares and up to 675,000 pre-funded warrants, each paired with a warrant to buy one common share. Common-share units are priced at $5.50, while pre-funded warrant units cost $5.4999. The accompanying warrants carry a $7.50 exercise price and expire after 18 months or 30 days after Edesa announces Phase 2 topline data for EB06 in vitiligo, whichever comes first. Underwriters have a 30-day option to buy up to 681,825 additional shares and accompanying warrants. The offering is expected to close around Aug. 21, with Guggenheim Securities as sole book-running manager. Edesa plans to use net proceeds for general corporate purposes, including working capital, research and development, manufacturing costs and capital expenditures. The transaction was conducted under an effective shelf registration statement. EDSA trades below its 20-day simple moving average of $5.35, 50-day average of $6.23 and 100-day average of $7.85, while sitting just below its 200-day average of $5.10. Resistance is near $5.35, with longer-term support at $5.10. The stock remains up 144.10% over the past 12 months but is far below its 52-week high of $20.32. The latest analyst rating is Buy with a $21.00 price target, while Spark, an AI-powered analyst platform, rates the stock Neutral with a score of 48, citing no revenue, persistent losses and continuing cash burn despite a low-debt balance sheet. Edesa focuses on host-directed therapeutics for inflammatory and immune-related diseases, with programs spanning vitiligo, chronic allergic contact dermatitis and acute respiratory distress syndrome. Some programs receive Canadian and U.S. government funding. The company has average trading volume of 141,563 shares and a market capitalization of $54.47 million. The new capital is expected to strengthen Edesa's financial resources as it advances its immuno-inflammatory disease pipeline in dermatology and respiratory therapeutics.